Olgu Sunumu

Serotonin Syndrome, Rhabdomyolysis and Cardiovascular Toxicity in Venlafaxine Poisoning: A Case Report

Venlafaxin Zehirlenmesinde Serotonin Sendromu, Rabdomyoliz ve Kardiyak Toksisite: Olgu Sunumu

Elif DOĞAN BAKI
Antalya Eğitim Araştırma Hastanesi Anesteziyoloji AD, Antalya

Abstract

More selective antidepressant agents are increasingly being used on first-line treatment. We present a case of 6gr venlafaxine intoxication with rhabdomyolysis, cardiac toxicity including patologic Q and serotonin syndrome. The patient was haemodynamically stable but muscular rigidity, hyperreflexia, dilated pupils and raised creatinin cinase (CK) were prominent on presentation to our Intensive Care Unit (ICU). It was seen that venlafaxine causing cardiac toxicity and death after large overdoses in the literature. Physicians should be aware of rhabdomyolysis and cardiac toxicity with venlafaxine poisoning.

Keywords: rhabdomyolysis, serotonin syndrome, venlafaxine

Özet


Anahtar Kelimeler: rhabdomyoliz, serotonin sendromu, venlafaxin

Introduction

Venlafaxine is a phenylethylamine derivative whose pharmacological mechanisms of action are related to inhibition of serotonin and norepinephrine neuronal reuptake (1). It is associated with a number of predictable adverse effects that are generally mild, including tachycardia, increased blood pressure, fatigue, headache, dizziness and dry mouth (2). Many of the newer antidepressants have been shown to be safer in overdose compared with the older tricyclic antidepressants. Venlafaxine appears to be more toxic than the newer antidepressants with a higher rate of fatalities (3), increased risk of seizures (4) and cardiac toxicity reported with massive ingestions (5). We present a case of an intoxication to the serotonin noradrenergic reuptake inhibitors venlafaxine.

Case Report

A 24-year old young man with a history of depression was admitted to the emergency department four hours after intoxication with the antidepressant venlafaxine. He reported to have ingested a total of 6gr of the extended-release formulation. He had not taken any other medications or alcohol. He was transferred to our ICU (Intensive Care Unit). On presentation he was agitated, disorientated, had muscular rigidity, hyperreflexia and his pupils were dilated and responsive to light. He was haemodynamically stable with a blood pressure of 137/86 mmHg and a sinus tachycardia of 120 to 140 beats/min. There were no signs of respiratory distress. His axillary temperature was 37.2C. His treatment was started with gastric lavage and activated charcoal. Routine blood analysis was performed. Leucocytosis (18.3 x10^9/l) was found and returned to normal within five days. Creatine
sodium bicarbonate increases cardiac contractility and prevents ventricular ectopies. Renal function was not affected. Miyoglobin values were increased to 3548 ng/ml and returned normal within three days. Also LDH was increased to 166 U/l and returned normal within three days too. All other electrolytes, blood urine nitrogen, total protein, creatinin, glucose, hepatic transaminases and coagulation study were within normal range. Nausea, sweating and muscle rigidity and agitation were prominent. Midazolam 1-2 mg was administered for his agitations. Three days later he became fully orientated and muscle rigidity was improved. When we detected pathological Q in his initial electrocardiogram (ECG) (six hours after ingestion) we wanted consultation from Cardiology Department. They also saw pathological Q and incomplete left branch block with prolonged QRS in his ECG. They found no abnormalities in his ecocardiography. Treatment was started with Karvedilol by their suggestion. Twelve hours after ingestion pathological Q were prominent in his ECG. Pathological Q was disappeared forty four hours later after ingestion. Thereafter, we saw his ECG normal at the fourth day of ICU.

**DISCUSSION**

Venlafaxine is an antidepressant that causes selective inhibition of neuronal reuptake of serotonin and norepinephrine with little effect on other neurotransmitter systems in the liver by cytochrome P450 enzyme system. Because of genetic polymorphisms, the metabolism of venlafaxine varies between patients. The primary route of excretion of venlafaxine and its metabolites is renal elimination, but is not possible to eliminate venlafaxine by haemodialysis. Several cases of seizures indicating neurological toxicity, tachycardia and QRS prolongation indicating cardiac toxicity as well as serotonin syndrome have been reported following a venlafaxine overdose (6, 7). The serotonin syndrome is a potentially life-threatening disorder of excessive serotonergic activity. It presents as a triad of altered mental status, neuromuscular abnormalities and autonomic dysfunction (8). The patient reported in this case had clinical signs and symptoms of an altered mental status, autonomic disorders (tachycardia, pupillary dilatation, dry mouth, tremor and sweating), muscular rigidity. Guided by the Sternbach criteria the diagnosis of the serotonin syndrome was seen in our patient (9). The raised plasma CK reported in our patient is most likely to have originated from skeletal muscle. Wilson et al determined a relationship between venlafaxine ingestion and acute muscle injury in their study (10). And they also suggested that CK levels might not become elevated until more than 12hr post-ingestion. In our case CK levels increased after 10hr post-ingestion. Therefore, measurement of CK levels immediately after an ingestion might underestimate the true prevalence of acute myopathy after venlafaxine overdose.

Venlafaxine poisoning is also associated with high prevalence of cardiovascular adverse effects. A previous study by Howell et al. on the cardiovascular toxicity of venlafaxine in overdose concluded that venlafaxine overdose is associated with a prolonged QT in ECG and this may pose an arrhythmogenic risk, despite no cases of malignant arrhythmias occurring in their study (11). In our case pathological Q and incomplete left branch block with prolonged QRS were seen. It was seen that venlafaxine causing cardiac toxicity and death after large overdoses in the literature. There was one report of an ingestion of 30g venlafaxine overdosage resulted in death (12). There is one report of QRS widening after a dosage of 3g; however the patient also ingested thioridazine (13). Other reports all include doses>8g (5), where patients also manifest other features of venlafaxine toxicity, including seizures and serotonin toxicity, and there is a significant risk of death. No seizures were seen in our patient ingested 6g of venlafaxine but pathological Q and incomplete left branch block with prolonged QRS were prominent and his ECG was normal within three days.

Due to the large distribution volume of venlafaxine, forced diuresis, dialysis, haemoperfusion and exchange transfusion are of no benefit. Activated charcoal should be administered to prevent absorption and might be useful when administered timely.

Venlafaxine remains a commonly prescribed antidepressant and will continue be taken in overdose. Venlafaxine poisoning is associated with cardiovascular adverse effects. Routine cardiac monitoring and ECG is necessary in venlafaxine overdose of mas-
Serotonin Syndrome, Rhabdomyolysis and Cardiovascular Toxicity In Venlafaxine Poisoning
Venlafaxin Zehirlenmesinde Serotonin Sendromu, Rabdomyoliz ve Kardiyak Toksisite

REFERENCES
